A previous study shows that Hsp60 not only interacts with, but also activates human hepatitis B virus polymerase, HBV Pol (S. G. Park and G. Jung, 2001, J. Virol. 75, 6962-6968). To provide a more detailed analysis of the relationship between the two proteins, (i) the binding sites on human HBV Pol for Hsp60 and (ii) the effect of pregenomic RNA on human HBV Pol-Hsp60 binding were analyzed. The binding sites on human HBV Pol were mapped with several deletion mutant proteins of the Pol expressed in insect cells by using recombinant baculovirus. Immunoprecipitation of each deletion mutant protein by M2 beads showed that binding of Hsp60 to human HBV Pol requires two minimal sites on human HBV Pol: amino acids 1 to 199 (TP) and amino acids 680 to 842 (RH). Human HBV Pol was also shown to bind to Hsp60 in HepG2 cells, the host cell line for human HBV. In addition, Hsp60 binding to the Pol was found to be dispensable to pregenomic RNA binding to human HBV Pol. Overall, this article infers that Hsp60 activates human HBV Pol through binding at the TP and RH domains of the Pol and the Pol binding to Hsp60 does not require pregenomic RNA.
INTRODUCTION
Human hepatitis B virus (HBV), a member of the hepadnavirus family, is an enveloped, partially doublestranded DNA virus (for reviews, see Ganem and Varmus, 1987) . It is also associated with the development of hepatocellular carcinoma and liver cirrhosis (Beasley et al., 1981) . After the viral infection of hepatocytes, viral DNA is converted to covalently closed circular DNA (cccDNA) in the nucleus (Kann et al., 1999; Mason et al., 1983; Seeger and Mason, 1996; Tagawa et al., 1986) through which four unspliced transcripts are produced (for reviews, see Ganem and Varmus, 1987) . This viral genome is replicated through reverse transcription of pregenomic RNA. Pregenomic RNA is one of the four unspliced transcripts mentioned above that encodes for human HBV polymerase (HBV Pol) (Huang and Summers, 1991) . The reverse transcription is initiated by priming through the 63rd tyrosine residue of human HBV Pol, which provides the hydroxyl group needed for primer synthesis (Zoulim and Seeger, 1994) . During the priming, three to four nucleotides are synthesized by human HBV Pol at the bulge region of the epsilon stem-loop region in pregenomic RNA. The synthesized oligonucleotides transfer to the direct repeat (DR) 1 region and functions as primers for (Ϫ)-stranded DNA synthesis (Seeger et al., 1986) . During DNA synthesis, the RNase H domain, which is in the carboxyl terminal region of human HBV Pol, hydrolyzes the RNA template, in this case pregenomic RNA (Radziwill et al., 1990) . After completion of (Ϫ)-stranded DNA synthesis, the (ϩ)-stranded DNA is synthesized by the Pol using the (Ϫ)-stranded DNA as the template. During this process, unhydrolyzed pregenomic RNA is utilized as the primer for synthesis of (ϩ)-stranded DNA .
In the initiation of HBV genome replication, the interaction between HBV Pol and the epsilon stem-loop region in pregenomic RNA is essential. It has been well known that this interaction is critical to pregenomic RNA packaging and the above priming process (Pollack and Ganem, 1993) . This interaction is also known to have cis-preference, which is supposed to be a cotranslational event (Junker-Niepmann et al., 1990) . In in vitro translation systems, it has been reported that binding between duck HBV Pol and the epsilon stem-loop region is facilitated by the Hsp90 complex which includes Hsp90, p23, Hsp70, and so on (Hu and Seeger, 1996; Hu et al., 1997) . Recent studies show that duck HBV Pol expressed in the Escherichia coli system shows in vitro priming activity only if the Pol is assisted by Hsp90 (Hu and Anselmo, 2000) . In addition, it has been suggested that Hsp90 binding for duck HBV Pol may have induced conformational changes in the Pol, which facilitates the binding of duck HBV Pol to the epsilon stem-loop region (Hu and Seeger, 1996; Hu et al., 1997) . It was also shown that Hsp90 could stabilize duck HBV Pol activity after priming (Hu and Anselmo, 2000) . Another chaperone, Hsp60, has also been identified as a human HBV Pol binding protein. It functions as an activating factor for human HBV Pol, which was shown through an analysis of human HBV Pol expressed in insect cells using the recombinant baculovirus system (Park and Jung, 2001) . Although Hsp60 has been well known as a chaperonin in mitochondria, recent studies indicate that Hsp60 is also able to function as an activating factor. For example, pro-caspase-3 and the prion protein are activated by Hsp60 (Edenhofer et al., 1996; Samali et al., 1999; Xanthoudakis et al., 1999) .
The biochemical and functional studies of human HBV Pol are made possible by the high expression level of human HBV Pol in the recombinant baculovirus system (Lanford et al., 1995 (Lanford et al., , 1997 (Lanford et al., , 1999 . The human HBV Pol obtained in the insect cell system is active in in vitro priming (Lanford et al., 1995) from which the fact that the insect cells provided the factors required for human HBV Pol maturation can be inferred. Formerly, Hsp60 was shown to bind to and function as an activating factor for human HBV Pol (Park and Jung, 2001) . In this article, a more detailed interaction between human HBV Pol and Hsp60 was sought. The binding sites on human HBV Pol for Hsp60 were identified to be at the TP (amino acids 1-199) and the RH (amino acids 680-842) domains of human HBV Pol. These sites were suggested to be modulation sites. Also through this experiment, the binding between human HBV Pol and the Pol binding to Hsp60 does not require pregenomic RNA, although Hsp60 affected human HBV Pol priming activity.
RESULTS

Expression of human HBV Pol deletion mutant proteins in insect cells
A previous study indicates that Hsp60 interacts with human HBV Pol and this interaction is required for human HBV Pol activation (Park and Jung, 2001) . The activation of human HBV Pol may be modulated at its binding site for Hsp60. To analyze the binding sites in human HBV Pol, we made constructs for expression of human HBV Pol deletion mutant proteins: amino terminal deletion, internal deletion, and carboxyl terminal deletion mutant proteins. Each recombinant baculovirus was generated by the BAC-TO-BAC system as shown under Materials and Methods. Each deletion mutant protein was expressed in Sf-9 cells and immunoprecipitated by M2 agarose beads. These immunoprecipitated proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining. Figure 1A shows that each deletion mutant protein immunoprecipitated by M2 agarose beads appears to be in the expected apparent molecular weight. To confirm that proteins in the bands were the correct FLAG-fused deletion mutant proteins, immunoblot analyses were performed with the M2 monoclonal antibodies. Each purified band was immunostained by the M2 monoclonal antibodies (Fig. 1B) , indicating that the proteins were successfully expressed in the insect cells. In the case of FPol1-199E, the molecular weight is very similar to the light chain of the M2 monoclonal antibody heavily stained with anti-mouse secondary antibodies (Fig. 1B, lane 4) . This resulted in overlapping of the two bands.
Hsp60 binds to the TP and the RH domains of human HBV Pol but one site is enough for binding of Hsp60 to human HBV Pol Each deletion mutant protein of human HBV Pol was expressed in Sf-9 cells. The expressed proteins were immunoprecipitated by M2 agarose beads and analyzed by SDS-PAGE and Coomassie blue staining. In the Coomassie blue stained gel, we found that the Hsp60 band did not appear in some lanes of the deletion mutant proteins ( Fig. 1A) . Human HBV Pol of these bands had deletions in both amino acids 1 to 177 and amino acids 680 to 842. In other words, the mutant proteins that did not contain the two regions did not bind to Hsp60. These binding regions represent the TP (amino acids 1-199) and the RH (amino acids 680-842) domains of human HBV Pol. To confirm that each copurified Hsp60 band was in fact Hsp60, an immunoblot analysis was performed using anti-Hsp60 polyclonal antibodies ( Fig. 2A ). This analysis showed that the bands were in fact Hsp60 ( Fig. 2A ). Levels of Hsp60 were almost same in total extract of each cell ( Fig. 2B ) and this indicates that the above results were not caused by variation of Hsp60 level in cells. Conclusively, binding of Hsp60 to human HBV Pol requires two minimal regions of human HBV Pol, TP (amino acids 1-199) and RH (amino acids 680-842), but one of the two binding regions is enough for binding of human HBV Pol to Hsp60 (Fig. 2C ).
Human HBV Pol expressed in HepG2 cells, the host cell line, also binds to Hsp60
To test whether human HBV Pol binds to Hsp60 in mammalian cells especially in hepatocytes, a MBP (40-kDa) fused-human HBV Pol protein was expressed in the hepatocyte cell line, HepG2 cells ( Fig. 3A) . Because the expression level of the Pol in HepG2 cells is low, immunoblot analyses with anti-MBP and anti-Hsp60 antibodies were performed. The expressed MBP fused-human HBV Pol (MBP-Pol) complex was immunoprecipitated with anti-MBP monoclonal antibodies and analyzed by an immunoblot analysis using anti-MBP polyclonal antibodies. In the immunoblot analysis, bands of smaller molecular weight than the full-length MBP-Pol complex (130-kDa) appeared to be immunostained (Fig. 3A) . These bands may be bands of MBP-Pol degradation products because these bands do not appear in the negative control and also the molecular weight is smaller than full-length human HBV Pol molecular weight. The negative control was prepared by transfection of pCMV/ MBP into HepG2 cells by the same methods of pCMV/ MBP-Pol transfection. Immunoblot analysis with anti-Hsp60 polyclonal antibodies was performed with immunoprecipitated MBP-Pol. Figure 3B indicates that Hsp60 is present in the MBP-Pol fraction, but not in the negative control. This result strongly supports the binding of human HBV Pol with Hsp60 in mammalian host cells. Human HBV Pol-Hsp60 binding does not require human HBV Pol-pregenomic RNA binding Previous reports show that human HBV Pol, expressed in insect cells using the recombinant baculovirus expression system, forms a complex with Hsp60 (Park and Jung, 2001) and with pregenomic RNA (Lanford et al., 1995) . To test the effect of pregenomic RNA on human HBV Pol-Hsp60 binding, first, we constructed FPol⌬E in which the 3Ј nontranslated region containing the epsilon stem-loop region was deleted from FPolE ( Fig. 4 ). Immunoprecipitation of this construct by M2 beads showed that Hsp60 still binds with human HBV Pol though the epsilon stemloop region is absent in the human HBV Pol complex (Fig. 5A) . Additionally, the amount of Hsp60 bound to FPol⌬E was observed to be constant compared to the amount of Hsp60 bound to FPolE (Fig. 5A, left panel) . From the immunoblot analysis, human HBV Pol binding to the epsilon stem-loop region in pregenomic RNA is observed to have no effect on human HBV Pol-Hsp60 binding, too (Fig. 5A, right panel) . However, there is still a possibility that the presence of other regions of pregenomic RNA can affect human HBV Pol-Hsp60 binding. Figure 5B shows that Hsp60 still binds with human HBV Pol though treated with three types of nucleases: RNase A, DNase I, and micrococcal nuclease. Moreover, the amount of Hsp60 bound to human HBV Pol did not decrease compared to the control that was not treated with the nucleases (Fig. 5B) . The results of nuclease treatments indicate that Hsp60 binding for human HBV Pol is not mediated by any nucleic acids including the pregenomic RNA. The above results indicate that human HBV Pol-Hsp60 binding does not require epsilon RNA binding to human HBV Pol.
DISCUSSION
A previous study shows that Hsp60 binds to human HBV Pol and that this process is important for Pol activation in in vitro conditions (Park and Jung, 2001) . Hsp60 is a new host factor for human HBV Pol activation and this may be helpful for understanding the mechanism of human HBV DNA replication. Generally, Hsp60 is abundant in cells and functions as a chaperone assisting in protein folding (Bukau and Horwich, 1998) . Hsp60 is mainly localized in the mitochondria matrix, but the protein can be found in other regions such as the cell surface and the cytosol (Itoh et al., 1995 (Itoh et al., , 1999 Gupta, 1996, 1997) . In the mitochondria matrix, Hsp60 assists the folding of proteins imported into the mitochondria matrix (Bukau and Horwich, 1998) . In extra mitochondria regions, it has been reported that Hsp60 functions as an autoantigen on the cell surface (Itoh et al., 1995) , but its functions in the cytosol have not yet been discovered. In the case of yeast DNA Pol, Hsp60 was copurified with this Pol and was found to function as FIG. 4. Constructions. (A) The pFPolE construction was previously described (Park and Jung, 2001) . In short, the transfer-vector pFPolE was cloned by an insertion of a fragment downstream of the polyhedrin promotor. The fragment contains human HBV Pol ORF, the epsilon stem-loop region, and 3Ј NTR containing DR2, DR1. This epsilon stemloop region is the template in human HBV Pol priming. The transfervector pFPol⌬E was constructed through deletion of 3Ј NTR. As a negative control for the RNA binding assay, pEpsilon was constructed by insertion of the 3Ј NTR into pFASTBAC. Each recombinant baculovirus (vFPolE, vFPol⌬E, and vEpsilon) was generated by the BAC-TO-BAC system. Transfer vectors for expression of deletion mutant proteins of human HBV Pol were constructed through PCR-mediated mutagenesis and recombinant baculoviruses were generated as described under Materials and Methods. The proteins were expressed in Sf-9 cells using each generated recombinant baculovirus. (B) To express human HBV Pol in HepG2 cells, pCMV/MBP Pol was constructed. The process for its construction is described in our previous study (Cho et al., 2000a) . As the negative control, pCMV/MBP was constructed by the insertion of MBP ORF from pMal-c2 into pCMV vector.
FIG. 3. Human HBV Pol expressed in HepG2 cells also binds to
Hsp60. The plasmids, pCMV/MBP-Pol (lane 2), containing MBP fusedhuman HBV pol downstream of the CMV promoter were transfected into HepG2 cells by calcium phosphate transfection method. Two days after the transfection, the transfected cells were harvested, lysed, and subjected to immunoprecipitation with anti-MBP monoclonal antibodies as previously described (Cho et al., 2000a) . (A) Half of the immunoprecipitated protein of each sample was analyzed by an immunoblot analysis with anti-MBP polyclonal antibodies (Cho et al., 2000a) . (B) The remaining half of each sample was analyzed by an immunoblot analysis with anti-Hsp60 polyclonal antibodies. stimulating factor I (SFI) (Brown et al., 1990; Smiley et al., 1992) . As indicated above, Hsp60 is localized in various regions in cells and has diverse functions as a chaperone, an autoantigen, a protein activation factor, and so on.
In this article, we analyzed in more detail the binding property of Hsp60 for human HBV Pol. The recombinant baculovirus system was used to express human HBV Pol in insect cells because expression of human HBV Pol in hepatocytes is very difficult and sequences of Hsp60 are highly conserved between eukaryotes. Binding site analysis by using many deletion mutant proteins of human HBV Pol showed that binding of Hsp60 to human HBV Pol requires two minimal sites on human HBV Pol: amino acids 1 to 199 (TP) and amino acids 680 to 842 (RH). In addition, one of the two binding sites was found to be sufficient for binding of Hsp60 to human HBV Pol. If binding was caused by overexpression of the proteins, all of the Pol deletion constructs must have bound to Hsp60. These results indicate that the bindings are specific. Therefore, the results of binding site analysis indicate a possibility that Hsp60 activates the human HBV Pol by binding to TP and RH domains of the Pol. The binding between Hsp60 and the TP and the RH regions of the human HBV Pol is interesting. Recently, another of our studies showed that human HBV Pol also binds to Hsp90 (Cho et al., 2000a,b) and that this binding is important for showing in vitro priming activity (data not shown). It has been reported that Hsp90 binds to the TP and the RT domains in both human and duck HBV Pol (Cho et al., 2000a; Hu and Anselmo, 2000) . Of the two binding sites, the TP domain overlaps with Hsp60 binding site. To solve the relationship between the two chaperones, we needed to test whether their relationship is temporal or spatial. A recent report of duck HBV Pol shows that GroEL, a protein in the Hsp60 family in E. coli, also binds to the Pol and it has been predicted that GroEL assists in the Pol maturation (Hu and Anselmo, 2000) . This study suggests that binding of GroEL to duck HBV Pol is important for in vitro priming activity before the binding of Hsp90 (Hu and Anselmo, 2000) , providing the possibility that Hsp60 may interact with human HBV Pol before it interacts with Hsp90. However, the role of Hsp60 on human HBV Pol is still uncertain except for its role in activation and the binding sites of Hsp60 on human HBV Pol.
During priming, binding of human HBV Pol on pregenomic RNA containing the epsilon stem-loop region is essential for synthesis of (Ϫ)-stranded DNA of the human HBV genome. In the case of duck HBV Pol, binding of HBV Pol for the epsilon stem-loop region is facilitated by the Hsp90 complex (Hu and Seeger, 1996; Hu et al., 1997) . To test the relationship between pregenomic RNA and Hsp60, the following experiments were performed. An analysis of whether pregenomic RNA binding to human HBV Pol influences for human HBV Pol-Hsp60 binding or not, pFPol⌬E was constructed and nucleases were treated. In addition, Hsp60 also binds to FPol⌬E that does not contain the epsilon stem-loop region. Nuclease treatments also did not affect the binding between human HBV Pol and Hsp60. These results show that Hsp60 binding to human HBV Pol does not require epsilon RNA binding to human HBV Pol.
In this article, we found that Hsp60 binds to both the TP and the RH domains of human HBV Pol, which may be modulation sites for Pol activation by Hsp60. Moreover, this binding is dispensable to pregenomic RNA binding to human HBV Pol. Recently, it has been reported that Hsp60 also participates in the activation of human immunodeficiency virus type 1 integrase (Parissi et al., 2001) . Therefore, this article and our data indicate that Hsp60 plays a role in activation of viral enzymes. The above data provide a more in-depth analysis of the relationship between human HBV Pol and Hsp60. These results may helpful for further analysis of human HBV Pol-Hsp60 functional interaction.
MATERIALS AND METHODS
Plasmid construction
The construction of baculovirus transfer vector pFPolE is as previously described (Park and Jung, 2001) . In short, the amino-terminal region of the human HBV Pol open reading frame (ORF) fused with a FLAG tag (Met-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-Leu) was generated by using PCR-mediated mutagenesis. Then, this fragment was cloned into a pFASTBAC vector (Park and Jung, 2001) . The remaining ORF including the carboxyl terminal region and the 3Ј nontranslated region (NTR) also was cloned into the above vector (Fig. 4) . In the case of the pFPol⌬E construct, a fragment starting from the EcoRI site which is behind the stop codon of human HBV Pol ORF to SalI site which is behind the poly(A) signal sequence in pFPolE was removed by enzymatic digestion. The overhanging fragments of the remaining pFPolE construct were filled in and then the newly formed blunt ends self-ligated (Fig. 4) . In the case of the pEpsilon construct, the fragment including amino acid 346 (XhoI site) of the Pol up to the poly(A) signal sequence (SalI site) was inserted into pFASTBAC (Fig. 4) . For deletion mutant protein expressions of human HBV Pol, the deletion fragments of human HBV Pol were generated through PCR-mediated mutagenesis (Fig. 4) . In each case, a deletion fragment was amplified with forward primers fused to the FLAG tag sequence at the 5Ј ends and reverse primers containing EcoRI restriction site and termination codon at the 5Ј ends. For each construct, the starting and terminating amino acids were given, followed by the construct name (e.g., FPol177-679E stands for the FLAG-internal deletion construct with an amino terminus that begins at amino acid 177 and a carboxyl terminus that ends at amino acid 679; the "E" represents the epsilon stem-loop region). For expression in HepG2 cells, we used previously constructed pCMV/MBP-Pol (Cho et al., 2000a) . For this construct, MBP fused-human HBV Pol ORF was cloned downstream of the CMV promoter in pCMV vector. The SV40 poly(A) signal sequence follows the human HBV Pol ORF. A pCMV/MBP was constructed by the insertion of MBP ORF into the above pCMV vector. MBP ORF was obtained from pMAL-c2 plasmids (New England BioLabs, Inc.). The methods of expression and immunoprecipitation of MBP fused-human HBV Pol were described in a previous study (Cho et al., 2000a) .
Cells and infections
Spodoptera frugiperda Sf-9 cell line was maintained in TNM-FH (Sigma) supplemented with 5% certified fetal bovine serum (Life Technology, Inc.). Recombinant baculoviruses were generated with the plasmid constructed above using the BAC-TO-BAC system (Life Technology, Inc.). For protein production, when the Sf-9 cells reached about 70% confluence, the recombinant baculoviruses (multiplicity of infection, 2 to 10) were added to the medium in which the cells were cultured and incubated for 2 h at 22°C. The medium was renewed with fresh medium and virus-infected cells were incubated at 27°C. Two days later, the infected cells were harvested and stored at Ϫ70°C until use. The HepG2 cells, the cell line for human hepatocytes, were cultured in MEM (Life Technology, Inc.) supplemented with 10% qualified fetal bovine serum (Life Technology, Inc.).
Immunoprecipitation of human HBV Pol using M2 beads
As previously indicated, Sf-9 cells were infected with each recombinant baculovirus for 2 days (Park and Jung, 2001) . Then the cells were lysed with 1 ml lysis buffer per 1 ϫ 10 7 cells on ice for 15 min. The lysis buffer contains 1 mM EDTA, 5 mM dithiothreitol, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 100 M leupeptin, and 50 U recombinant RNAsin (Promega) per ml added to phosphate-buffered saline (PBS). The extracts were cleared by centrifugation at 30,000 g for 15 min at 4°C. The cleared extracts were incubated with M2 agarose beads (Sigma) for 2 h on ice and the beads were washed sequentially once with 1 ml TNG (100 mM Tris-Cl, pH 7.5, 30 mM NaCl, and 10% glycerol), twice with 1 ml TNG with 1 M NaCl, and once again with 1 ml TNG. It is critical for the washing step with TNG ϩ 1 M NaCl to be longer than 5 min. The bound proteins were eluted once with 1ϫ SDS sample buffer. The purified proteins were frozen at Ϫ70°C until use. As otherwise indicated, Sf-9 cells for production of human HBV Pol were infected by vFPolE.
Immunoblot analysis
Each protein sample was electrophoresed on its appropriate percentage SDS-PAGE and subsequently transferred to a polyvinylidene difluoride (PVDF) mem-brane in a solution of 25 mM Tris-Cl, pH 8.3, 192 mM glycine, and 20% methanol. Each blot was incubated with the appropriate antibodies: anti-Hsp60 goat polyclonal N-20 antibody (Santa Cruz Biotechnology, Inc.), anti-MBP polyclonal antibody (Cho et al., 2000a) , and M2 monoclonal antibody (Sigma), each at dilution levels recommended by the manufacturers. The incubation steps were performed as described previously (Towbin et al., 1979) . The antibodies were detected by chemiluminescence (ECL System, Amersham Pharmacia Biotech).
Treatment of nuclease (RNase A, DNase I, micrococcal nuclease)
Following the purification of the FLAG-epitope fused human HBV Pol through the above purification step, M2 beads were downed by centrifugation at 700 g for 3 min and the supernatant was removed. After removal of the residual solution, 1 g/l RNase A (Sigma) in TNG, 1 U/l DNase I (Promega) in DNase I buffer (40 mM Tris-Cl, pH 7.4, 6 mM MgCl 2 , and 2 mM CaCl 2 ), or 3 U/l micrococcal nuclease (MBI Fermentas) in nuclease buffer (50 mM Tris-Cl, pH 8.8, 50 mM NaCl, and 5 mM CaCl 2 ) was added and the solution was incubated in a water bath of 37°C. This solution was periodically agitated for resuspension of the M2 beads. After incubation, the M2 beads bound to the proteins were sequentially washed once with TNG, twice with TNG and 1 M NaCl, and a last time with TNG. The proteins bound to the M2 beads were eluted with 1ϫ SDS sample buffer and analyzed by an immunoblot with anti-Hsp60 polyclonal antibodies (Santa Cruz Biotechnology, Inc.).
